Quick Answer
Rapport Therapeutics, Inc. reported Cash and Equivalents of $52.65 million for fiscal year 2025.
Rapport Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $52.65M | -7.3% |
| 2024 | $56.80M | -19.0% |
| 2023 | $70.17M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $251.36M | +539.4% | +356.5% |
| June 30, 2025 | $55.07M | -50.0% | -4.4% |
| March 31, 2025 | $57.60M | -22.4% | +1.4% |
| December 31, 2024 | $56.80M | -19.0% | +44.5% |
| September 30, 2024 | $39.31M | -75.3% | -64.3% |
| June 30, 2024 | $110.16M | +38.5% | +48.3% |
| March 31, 2024 | $74.27M | — | +5.8% |
| December 31, 2023 | $70.17M | — | -56.0% |
- Rapport Therapeutics, Inc. showed a decrease of -7.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Rapport Therapeutics, Inc.’s cash and equivalents has declined by 25.0% (from $70.17 million to $52.65 million).
- The most recent figure is from Rapport Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: